GlassScriptPhysician profile
Darrell Loren Southern
NPI 1548268907
$5,091.68
in general payments reported to CMS, 2019-2025
9 companies · $323 in 2025
The $323 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,937 · 2020: $264 · 2021: $126 · 2022: $168 · 2023: $137 · 2024: $138 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $598.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $3,745.34 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $558.86 | 2020-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $303.68 | 2019-2024 | Trelegy Ellipta |
| Genentech USA, INC. | $176.42 | 2019 | |
| Genzyme Corporation | $138.10 | 2020-2022 | |
| Ars Pharmaceuticals Operations, INC. | $124.87 | 2025 | Neffy |
| Hikma Pharmaceuticals USA | $16.47 | 2024 | Ryaltris |
| Aimmune Therapeutics, INC. | $15.30 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $12.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darrell Southern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.